Transplant immunology最新文献

{"title":"Oral cyclosporine a nanosuspension for improved immunosuppressive efficacy: In vivo cytokine profiling in rats","authors":"Çağman Tan ,&nbsp;Sıla Gülbağ Pınar ,&nbsp;Nevin Çelebi","doi":"10.1016/j.trim.2025.102301","DOIUrl":"10.1016/j.trim.2025.102301","url":null,"abstract":"<div><h3>Background</h3><div>Cyclosporine A (CycA) is a cornerstone immunosuppressant in transplantation, but its poor solubility and variable bioavailability limit therapeutic efficacy. Nanosuspension technology offers an innovative formulation strategy to enhance oral absorption and potentially improve immunomodulatory effects.</div></div><div><h3>Methods</h3><div>Wistar rats (<em>n</em> = 4/group) received oral CycA as coarse powder, physical mixture, commercial product, or nanosuspension. Serum cytokines and chemokines (IL-4, IL-5, IL-10, IL-13, IL-17 A, Eotaxin, GRO-α, IP-10, MCP-1, MCP-3, MIP-1α, MIP-2, Rantes) were quantified on days 7, 14, and 21. Data were expressed as mean ± SD. Statistical analysis was performed using Mann–Whitney <em>U</em> test with Benjamini–Hochberg correction for multiple comparisons.</div></div><div><h3>Results</h3><div>At day 21, IL-10 levels were significantly higher in the nanosuspension group compared to control and coarse powder (adjusted <em>p</em> = 0.041), confirming nanosuspension-mediated IL-10 upregulation. IL-13 was also elevated in nanosuspension and commercial product groups versus control (p_adj = 0.048). IL-4 was significantly reduced in the nanosuspension group at both day 7 (p_adj = 0.042) and day 21 (p_adj = 0.049). IL-5 levels increased in the nanosuspension group at day 21 compared to control and coarse powder (p_adj = 0.037). No statistically significant differences were detected for IL-17 A or chemokines, although descriptive trends suggested altered profiles in the nanosuspension group.</div></div><div><h3>Conclusion</h3><div>CycA nanosuspension selectively modulates cytokine networks by elevating IL-10, fine-tuning Th2 cytokines (IL-4, IL-5, IL-13), and trending toward chemokine regulation. These findings highlight nanosuspension technology as a promising strategy to enhance CycA's immunosuppressive efficacy, with potential implications for transplantation.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102301"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of intravenous immunoglobulin (IVIG) treatment on BK viremia and BK virus-associated nephropathy (BKVN) in kidney transplant patients: A systematic review","authors":"Maryam Hassanian ,&nbsp;Mojgan Mortazavi ,&nbsp;Firouzeh Moeinzadeh","doi":"10.1016/j.trim.2025.102288","DOIUrl":"10.1016/j.trim.2025.102288","url":null,"abstract":"<div><h3>Background</h3><div>There are limited approved therapeutic options for BK viremia management in kidney transplant patients. We performed the present study to investigate the effect of Intravenous immunoglobulin (IVIG) treatment on BK viremia and BK virus-associated nephropathy (BKVN) in kidney transplant patients.</div></div><div><h3>Methods</h3><div>A systematic search was performed in Web of Science, Embase, PubMed, and Scopus for studies that investigated the effect of IVIG therapy on BK viremia and BKVN in kidney transplant patients. Observational studies and case series were considered eligible for inclusion in this study. Data extraction was performed by two independent investigators by a standard checklist.</div></div><div><h3>Findings</h3><div>Our results indicated that IVIG treatment in patients with BKVN was effective in BK viremia treatment and nephropathy. In addition, preemptive IVIG significantly decreased the risk of BK viremia and BKVN in high-risk patients. However, it does not seem that IVIG treatment has a beneficial impact on allograft function. Because no significant improvement in serum levels of creatinine has been reported in previous studies. In addition, the presence of interstitial fibrosis or tubular atrophy was reported in studies with histopathological examinations of renal biopsies following IVIG treatment.</div></div><div><h3>Conclusion</h3><div>IVIG therapy combined with immunosuppression reduction may be beneficial in treating BK viremia and BKVN, but its impact on graft function and survival remains uncertain. Further studies are needed to clarify its role in kidney transplant outcomes.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102288"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145102939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De novo donor specific antibody (dnDSA) development with tacrolimus versus Belatacept based regimens in kidney transplant recipients","authors":"Cayla Kass ,&nbsp;Goni Katz-Greenberg ,&nbsp;Jason Bodner ,&nbsp;Scott Sanoff ,&nbsp;Alice Parish ,&nbsp;Alaattin Erkanli ,&nbsp;Jennifer Byrns","doi":"10.1016/j.trim.2025.102297","DOIUrl":"10.1016/j.trim.2025.102297","url":null,"abstract":"<div><h3>Purpose</h3><div>Belatacept has been associated with less de novo specific antibody (dnDSA) development, but few publications have compared the incidence of dnDSA development between tacrolimus and belatacept-based immunosuppression regimens. The purpose of this study was to investigate the differences in dnDSA development and clinical outcomes between these two maintenance regimens in kidney transplant.</div></div><div><h3>Methods</h3><div>This was a retrospective, single center, cohort study of patients transplanted between 2013 and 2019 who received a de novo belatacept or tacrolimus-based immunosuppression regimen. The primary outcome was the incidence of dnDSA development (MFI ≥ 1000) at 36 months. Secondary outcomes included renal function, biopsy proven rejection (BPAR), and patient/graft survival.</div></div><div><h3>Results</h3><div>Ninety patients met inclusion criteria. The primary outcome occurred in 4 (8.9 %) belatacept patients and 6 (13.3 %) tacrolimus patients, with an overall median time to dnDSA of 300 days (<em>p</em> = 0.51). Class II dnDSA development occurred in 3 (6.7 %) belatacept patients and 6 (13.3 %) tacrolimus patients. Belatacept patients had a lower, but not significantly different, rate of developing BPAR (4.4 % vs 13.3 %, <em>p</em> = 0.13) and had superior renal function at 36 months (median 66 ml/min vs 53 ml/min, <em>p</em> &lt; 0.01). Overall, there was excellent patient/graft survival at 36 months post-transplant.</div></div><div><h3>Conclusion</h3><div>De novo belatacept use did not result in a statistically significant difference in the development of dnDSAs but did show a numerically lower class II dnDSA and BPAR development. Overall, belatacept was associated with improved renal function as compared to tacrolimus-based regimens.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102297"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145081726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-6 amplifies corneal transplant alloimmunity by inducing dysfunctional IFN-γ- secreting Treg through the VEGFA-VEGFR1 axis","authors":"Seokjoo Lee,&nbsp;Akitomo Narimatsu,&nbsp;Neda Heydarian,&nbsp;Mark Krauthammer,&nbsp;Shilpy Bhullar,&nbsp;Yihe Chen,&nbsp;Sunil K. Chauhan,&nbsp;Thomas H. Dohlman,&nbsp;Reza Dana","doi":"10.1016/j.trim.2025.102284","DOIUrl":"10.1016/j.trim.2025.102284","url":null,"abstract":"<div><h3>Background</h3><div>Corneal allografts generally exhibit high acceptance due to the immune-privileged ocular microenvironment. Regulatory T cells (Treg) promote graft tolerance; however, in a vascularized milieu, they may acquire a pro-inflammatory phenotype. We investigated how dysfunctional Treg contribute to graft rejection through the VEGFA–VEGFR1 axis.</div></div><div><h3>Methods</h3><div>Treg were treated with IL-6 and VEGFA, and their phenotype—including FoxP3, IL-10, and IFN-γ—was evaluated with or without a VEGFR1 antagonist (αVEGFR1) using PCR, immunoblotting, ELISA, and flow cytometry. Suppressive function was assessed by T-cell proliferation assays, corneal cell death by Annexin V staining, and graft survival by adoptive transfer of dysfunctional Treg into a transplantation model.</div></div><div><h3>Results</h3><div>IL-6 reduced FoxP3 (<em>p</em> &lt; 0.0001) and upregulated VEGFR1 (<em>p</em> &lt; 0.001). IL-6 plus VEGFA further decreased FoxP3 (<em>p</em> &lt; 0.0001) and IL-10 (<em>p</em> &lt; 0.0001) while increasing IFN-γ (p &lt; 0.0001). αVEGFR1 reversed these effects, restoring FoxP3 (p &lt; 0.0001) and IL-10 (<em>p</em> &lt; 0.05) while reducing IFN-γ (<em>p</em> &lt; 0.001). Functionally, IL-6/VEGFA-pretreated Treg showed impaired suppression of effector T-cell proliferation (<em>p</em> &lt; 0.0001), an effect partially rescued by αVEGFR1 (<em>p</em> &lt; 0.001). In ex vivo assays, fresh Treg prevented, whereas dysfunctional IFN-γ–secreting Treg induced, corneal cell death (<em>p</em> &lt; 0.0001). In vivo, grafts injected with dysfunctional Treg were rejected within 3–7 weeks, while those with αVEGFR1-treated Treg showed improved survival and reduced cell death (<em>p</em> &lt; 0.0001).</div></div><div><h3>Conclusion</h3><div>IL-6 impairs Treg via VEGFR1 upregulation, driving IFN-γ secretion through the VEGFA–VEGFR1 axis and promoting corneal cell death and graft rejection.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102284"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144996996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relation between monocyte to high-density lipoprotein cholesterol ratio and prognosis in recipients after liver transplantation","authors":"Serafettin Okutan ,&nbsp;Hasan Saritas ,&nbsp;Serdar Saritas ,&nbsp;Semra Bulbuloglu ,&nbsp;Hüseyin Guneş","doi":"10.1016/j.trim.2025.102331","DOIUrl":"10.1016/j.trim.2025.102331","url":null,"abstract":"<div><h3>Background</h3><div>The end-stage liver diseases require liver transplantation as the life-saving solution. It is known that monocytes/macrophages and high-density lipoprotein cholesterol (HDL<img>C) have important contributions to the development of hepatic inflammation and oxidative stress before liver transplantation. However, the effect of monocyte/HDL-C ratio (MHR) on clinical progression and outcome in the post-transplant period are not fully understood. Our hypothesis is that the MHR value may be associated with poor vs. good outcomes after liver transplantation.</div></div><div><h3>Methods</h3><div>In our retrospective study, we included 464 liver transplant recipients. Patients' data were extracted from electronic and other paper records in our teaching/research hospital. The MHR values and other blood parameters (creatinine, total protein, albumin, etc.) were expressed as a mean and standard deviation, which were analyzed by the Pearson correlation test. The relationship between graft dysfunction and MHR was determined by ROC curve analysis.</div></div><div><h3>Results</h3><div>The mean age of liver transplant recipients was 45.8 ± 13.7 years. Nineteen percent of patients had liver failure due to Alcoholic Fatty Liver Disease (AFLD) and 34.5 % had liver failure due to hepatitis B virus. At the end of 3 months after liver transplantation, 84.5 % of liver transplant recipients were alive, 5.8 % experienced graft rejection and 5.17 % had an infection. There was a statistically significant improvement in total protein, albumin, liver function tests, and serum creatinine values of the survivors (all <em>p</em> &lt; 0.05). The MHR levels were significantly higher in patients who died after transplantation in comparison to those who survived before and after liver transplantation and these differences were statistically significant (<em>p</em> &lt; 0.01).</div></div><div><h3>Conclusion</h3><div>The increased MHR values of recipients after liver transplantation correlated with their risk of survival. Furthermore, the MHR value increased with increased MELD score and the number of days of hospitalization and was not affected by gender and age. MHR was higher in patients with chronic diseases. Patients with high MHR before and after transplantation should be monitored more closely in the perioperative period.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102331"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145614841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myth or reality: Graft versus host disease after autologous hematopoietic cell transplantation, a multicentre experience","authors":"Süreyya Yiğit Kaya ,&nbsp;Leylagül Kaynar ,&nbsp;Yaşa Gül Mutlu ,&nbsp;Mihriban Yıldırım ,&nbsp;İstemi Serin ,&nbsp;Duygu Nurdan Avcı ,&nbsp;Gülşah Akyol ,&nbsp;Osman Şahin ,&nbsp;Senem Maral ,&nbsp;Ömür Gökmen Sevindik","doi":"10.1016/j.trim.2025.102286","DOIUrl":"10.1016/j.trim.2025.102286","url":null,"abstract":"<div><div>Acute graft-versus-host disease (aGvHD) is a rare but clinically significant complication of autologous hematopoietic cell transplantation. The aim of this retrospective multicenter study was to evaluate the clinical features, outcomes and risk factors associated with autologous graft-versus-host disease (auto-GvHD) in 19 patients. The cohort included 12 multiple myeloma and 7 lymphoma patients with a median age of 58 years. All patients developed aGvHD, predominantly involving the gastrointestinal tract, skin or liver, with isolated organ involvement in the majority. Conditioning regimens commonly included melphalan and all patients underwent peripheral blood hematopoietic cell transplantation. First-line treatment with topical corticosteroids and systemic methylprednisolone was effective in most cases, while steroid-resistant GvHD was successfully treated with cyclosporine and ruxolitinib. Lenalidomide maintenance therapy in multiple myeloma patients did not lead to GvHD recurrence. No GvHD-related mortality was observed and complete responses were achieved in all treated cases. These findings underscore the importance of early detection and prompt treatment of auto-GvHD, particularly in high-risk populations and highlight the need for further research to elucidate its pathophysiology and optimise management strategies.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102286"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of everolimus with reduced tacrolimus versus standard tacrolimus in liver transplant recipients: A systematic review and meta-analysis of randomized controlled trials","authors":"Akash Kumar ,&nbsp;Mateen Ahmad ,&nbsp;Amna Hussain ,&nbsp;Khadija Mohib ,&nbsp;Muhammad Asjad Saleem ,&nbsp;Muhammad Saad ,&nbsp;Muhammad Ansab ,&nbsp;Ram ,&nbsp;Pinkey Kumari ,&nbsp;Nisha Kumari","doi":"10.1016/j.trim.2025.102317","DOIUrl":"10.1016/j.trim.2025.102317","url":null,"abstract":"<div><h3>Background</h3><div>Liver transplantation (LT) requires immunosuppression to prevent rejection while minimizing adverse effects. Tacrolimus (TAC) is standard but linked to nephrotoxicity and leukopenia. Everolimus (EVR) with reduced-dose TAC (rTAC) offers a potential alternative, potentially improving safety while preserving efficacy.</div></div><div><h3>Objectives</h3><div>To compare everolimus with reduced-dose tacrolimus (EVR + rTAC) versus standard tacrolimus (sTAC) in liver transplant recipients, assessing composite efficacy as the primary outcome, with graft loss, peripheral edema, mortality and evaluating safety via incidence of adverse events.</div></div><div><h3>Methods</h3><div>PubMed, Cochrane Library, and <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> were systematically searched from inception until 1st March 2025. Randomized controlled trials (RCTs) comparing everolimus with reduced-dose tacrolimus (EVR + rTAC) versus standard tacrolimus (TAC) in liver transplant (LT) recipients were included. A random-effects model was used for meta-analysis to calculate pooled risk ratios with 95 % confidence intervals (CI).</div></div><div><h3>Results</h3><div>A total of seven studies encompassing 1853 liver transplant recipients (EVR + rTAC: 1167; sTAC: 1174) were included. EVR + rTAC significantly reduced the risk of treated biopsy-proven acute rejection (tBPAR) compared to sTAC (RR: 0.67; 95 % CI: 0.47–0.94; <em>p</em> = 0.02; I² = 1 %). Renal function, assessed by estimated glomerular filtration rate (eGFR), was significantly better in the EVR + rTAC group (MD: 8.41; 95 % CI: 2.37–14.44; <em>p</em> = 0.006; I² = 86 %). Additionally, EVR + rTAC was associated with a significantly higher risk of peripheral edema (RR: 1.56; 95 % CI: 1.25–1.95; <em>p</em> &lt; 0.0001; I² = 0 %) and leukopenia (RR: 2.87; 95 % CI: 1.99–4.13; <em>p</em> &lt; 0.00001; I² = 0 %).</div><div>No significant differences were observed between the EVR + rTAC and sTAC groups regarding the composite efficacy outcome (RR: 0.79; 95 % CI: 0.62–1.00; <em>p</em> = 0.05; I² = 0 %), graft loss (RR: 1.25; 95 % CI: 0.73–2.14; <em>p</em> = 0.41; I² = 0 %), mortality (RR: 1.30; 95 % CI: 0.87–1.96; <em>p</em> = 0.20; I² = 0 %), or the incidence of serious adverse events (RR: 1.03; 95 % CI: 0.94–1.12; <em>p</em> = 0.52; I² = 79 %). Furthermore, no significant differences were noted regarding diarrhea, abdominal pain, headache, or hypertension.</div></div><div><h3>Conclusion</h3><div>Everolimus with reduced-dose tacrolimus (EVR + rTAC) showed comparable efficacy to standard tacrolimus, with no significant differences in graft loss or mortality. It significantly reduced the risk of acute rejection and improved renal function (higher eGFR) but increased the risk of leukopenia and peripheral edema. Further studies are needed to optimize this renal-sparing regimen.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102317"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Women recipients are at high risk for biopsy-proven acute rejection in spouse kidney transplantation","authors":"Sulin Luo ,&nbsp;Meifang Wang ,&nbsp;Xingxia Wang ,&nbsp;Tianlu Zhang ,&nbsp;Luying Guo ,&nbsp;Pengpeng Yan ,&nbsp;Junhao Lv ,&nbsp;Hongfeng Huang ,&nbsp;Wenhan Peng ,&nbsp;Jianyong Wu ,&nbsp;Jingyi Zhou ,&nbsp;Jianghua Chen ,&nbsp;Rending Wang","doi":"10.1016/j.trim.2025.102324","DOIUrl":"10.1016/j.trim.2025.102324","url":null,"abstract":"<div><h3>Background</h3><div>Spouse kidney transplantation represents a significant source of kidney donations. However, gender dynamics often result in husbands being recipients and wives being donors. Research on the immunological rejection and prognosis in wife recipients—who may develop immune memory due to pregnancy or sexual contact but lack preformed antibodies before transplantation—remains limited.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed 164 patients who underwent living spousal kidney transplantation at the First Affiliated Hospital of Zhejiang University between July 2007 and December 2021, with follow-up until December 2023.</div></div><div><h3>Results</h3><div>The study included 33 husband-to-wife transplant cases (Group W) and 131 wife-to-husband cases (Group H). Donors in Group W were older, had higher serum creatinine (SCr) levels, and donated heavier kidneys compared with donors in Group H (<em>p</em> &lt; 0.05). Group W recipients had a significantly higher incidence of biopsy-proven acute rejection within two years post-transplant than Group H. The rejection reversal rate in Group W (5/6, 83.3 %) was also higher than in Group H (2/7, 28.6%) during the same period. Postoperative follow-up revealed that Group H had significantly higher SCr levels and relatively lower estimated glomerular filtration rate (eGFR) than Group W. Additionally, Group H exhibited a slightly higher mortality rate.</div></div><div><h3>Conclusions</h3><div>Wife recipients experienced a higher incidence of biopsy-proven acute rejection but demonstrated lower SCr levels and higher eGFR within two years post-transplant. This outcome may be largely explained by the greater kidney weight of male donors.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102324"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145439318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High torque Teno virus load is associated with increased all-cause mortality risk in liver transplant recipients: a multicenter cohort study","authors":"Delal Akdag ,&nbsp;Andreas A. Rostved ,&nbsp;Nikolai Kirkby ,&nbsp;Allan Rasmussen ,&nbsp;Ulrik Lassen ,&nbsp;Claus L. Andersen ,&nbsp;Bo-Göran Ericzon ,&nbsp;Carl Jorns ,&nbsp;Helena Zhao ,&nbsp;William Bennet ,&nbsp;Fredrik Åberg ,&nbsp;Arno Nordin ,&nbsp;Jens G. Hillingsø ,&nbsp;Susanne D. Nielsen ,&nbsp;Hans-Christian Pommergaard","doi":"10.1016/j.trim.2025.102309","DOIUrl":"10.1016/j.trim.2025.102309","url":null,"abstract":"<div><div>Liver transplant recipients have twice the cancer risk than the general population, and de novo cancer is a leading cause of mortality after transplantation. Torque Teno Virus (TTV) is a potential marker of immune function. However, its association with long-term outcomes such as all-cause mortality and de novo cancer remains unexplored. In this Scandinavian multicenter cohort biobank study, plasma samples collected one year after transplantation were analyzed for TTV load to investigate its association with (1) all-cause mortality, (2) <em>any</em> de novo cancer, (3) de novo cancer excluding non-melanoma skin cancer (NMSC), and (4) NMSC using Cox regression analyses. Survival curves were plotted using Kaplan-Meier analysis. We analyzed the data of 625 liver transplant recipients. During a median follow-up of four years, 83 (13 %) recipients developed cancer (105 cancers). Of these, 39 were de novo cancers, excluding NMSC, and 66 were NMSCs. Overall, 47 recipients (8 %) died (all-cause mortality). Recipients with a high versus a low TTV load had an increased risk of all-cause mortality in the adjusted model (aHR, 5.31 [95 %CI 1.05–26.83]). The 5-year survival rates were 81 % and 100 % in the high- and low-TTV groups, respectively (<em>p</em> = 0.004). TTV load was not significantly associated with <em>any</em> de novo cancer or de novo cancer, excluding NMSC and NMSC. A high TTV load was associated with an increased risk of all-cause mortality in liver transplant recipients. With further validation, the TTV load can potentially serve as a risk stratification tool.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102309"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145245222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial and ethnic disparities in kidney transplantation","authors":"Macrae Kozody ,&nbsp;Roberta Buccilli ,&nbsp;Giovanni Faddoul ,&nbsp;Jorge Ortiz","doi":"10.1016/j.trim.2025.102289","DOIUrl":"10.1016/j.trim.2025.102289","url":null,"abstract":"<div><div>Social determinants of health, bias and genetic predisposition contribute to racial inequities in chronic kidney disease (CKD) and kidney transplant (KTX) allocation. Recognizing and addressing these complex factors leads to improvement in outcomes. This narrative review aims to discuss the current state of racial disparities surrounding KTX and identify where future efforts should be concentrated. The discussion focuses on data from the past 10 years (2015–2025). Overall mortality and graft loss is lowest in Hispanics and Asians and highest in Native Americans, perhaps due to the unique protective or detrimental social factors in these populations. Blacks have equal to better mortality than Whites, but worse graft survival. In an effort to identify paucities in the current literature, KTX outcomes by specific CKD etiologies are reviewed, including: diabetic nephropathy, focal segmental glomerulosclerosis, membranous nephropathy, lupus nephritis, vasculitis and polycystic kidney disease. Graft survival and mortality patterns for disease specific kidney transplant generally mirrors that of all cause KTX, but available data is limited. In recent years, racial disparities in CKD and transplant have improved, but still persist, representing the need for continued investigation and improvement. Future work should focus on continued identification and implementation of successful mitigation strategies and investigation where current literature is insufficient, such as diabetic nephropathy.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102289"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145055869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}